Grünenthal Initiates Phase I Trial of Novel NaV 1.8 Inhibitor for Non-Opioid Pain Management
核心洞察
Grünenthal has enrolled the first healthy volunteers in a Phase I trial of its proprietary voltage-gated sodium channel (NaV) 1.8 inhibitor, targeting non-opioid pain therapy.
The 70-participant trial comprises Single and Multiple Ascending Dose studies to evaluate safety, tolerability, and pharmacokinetics, with results expected in the second half of 2026.
The NaV 1.8 channel represents a clinically validated pain target that plays a significant role in triggering excitatory signals in nociceptive neurons.
Grünenthal announced that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor, marking a significant milestone in the development of non-opioid pain therapies. The orally administered investigational medicine aims to provide a therapeutic option across a range of acute and chronic pain conditions, with full trial results expected in the second half of 2026.
Trial Design and Objectives
The Phase I trial will involve 70 healthy volunteers and comprises both Single Ascending Dose and Multiple Ascending Dose components. The study aims to assess the safety and tolerability profile and the pharmacokinetic characteristics of the investigational medicine. Additionally, the trial will generate initial insights into the compound's pharmacology through a cold-pressor test.
"Inhibition of NaV 1.8 offers an exciting opportunity to provide patients with urgently needed non-opioid pain therapies," says Uli Brödl, Chief Scientific Officer at Grünenthal. "While we have seen the first medicine targeting NaV 1.8 receive FDA approval last year, we are committed to driving further innovation in this field where advanced assets may provide enhanced patient outcomes by blocking NaV 1.8 more comprehensively."
Mechanism of Action
The NaV 1.8 channel represents a clinically and genetically validated pain target among the nine different NaV channels in the human body. The channel plays a significant role in triggering excitatory signals in nociceptive neurons, which the human brain perceives as pain. Blocking the NaV 1.8 channel to suppress or prevent its excitatory signaling is expected to provide a significant analgesic effect across a range of chronic and acute pain conditions.
Market Context
This development follows the FDA approval of the first medicine targeting NaV 1.8 last year, establishing precedent for this therapeutic approach. Grünenthal's entry into clinical development represents continued innovation in the NaV 1.8 space, with the company positioning its asset as potentially providing more comprehensive channel blocking capabilities.
Grünenthal, headquartered in Aachen, Germany, operates as a global leader in pain management and related diseases. The science-based pharmaceutical company has affiliates in 28 countries across Europe, Latin America, and the U.S., with products available in approximately 100 countries. In 2024, Grünenthal employed around 4,300 people and achieved revenues of €1.8 billion.